Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0008 • ACR Convergence 2024
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Ashley Mahne¹, Ryan Rodriguez², Jessica Wang¹, Daniel Anaya¹, Joseph K. Cheng¹, Brandon Kwong¹, Jesus Banuelos³, Peter Starokadomskyy³, Soo Park³, Candice Gibson⁴, Shouvonik Sengupta¹, Simone Sandoval¹, Jazmin Bravo³, Jeanne Flandez¹, Shairaz Shah¹, Amanda Goodsell¹, Nicole Khoshnoodi¹, Jennifer Zeng¹, Santiago Foos-Russ¹, Mario Lorente¹, Jennifer Adrian¹, Timothy Klasson¹, Yong Zhang⁵, Jessica Seitzer⁶, Birgit Schultes⁵ and Tom Van Blarcom³, ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emerville, CA, ³Kyverna Therapeutics, Inc., Emeryville, ⁴Kyverna Therapeutics, Inc., Emerybille, ⁵Intellia Therapeutics, Inc., Cambridge, MA, ⁶Intellia Therapeutics, Inc., Cambridge
Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…
Abstract Number: 0106 • ACR Convergence 2024
IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS
Christina Donath¹, Sara Kahlown¹, Ryan Soares², Kamal Gautam², Mariam Saleh³, Banki Katalin⁴ and Andras Perl⁵, ¹SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, ²SUNY Upstate University Hospital, Department of Medicine, Internal Medicine Residency Program, Syracuse, NY, ³SUNY Upstate University Hospital, Syracuse, NY, ⁴SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, ⁵SUNY, Syracuse, NY
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune coagulopathy that causes microvascular and macrovascular thrombosis in both venous and arterial systems. This can occur as a…
Abstract Number: 0179 • ACR Convergence 2024
Bridging the Gap: Enhancing Diversity in Lupus Clinical Trials Through Investigator and Research Staff Engagement
Tessa Englund¹, Katherine Holben¹, Simone Frank², Khadeejatul-Kubraa Lawal¹, Julie Hsieh³, Christine Lee³ and Saira Sheikh¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²North Carolina Translational and Clinical Sciences Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³U.S. Food and Drug Administration, Silver Spring, MD
Background/Purpose: Lupus disproportionately affects diverse racial and ethnic minority populations, yet there is a significant disparity between those affected and those enrolled in clinical trials.…
Abstract Number: 0211 • ACR Convergence 2024
Characteristics of Hospitalizations and Outpatient Follow-up for Patients with SLE at an Academic Hospital Setting in Austin, Texas
Riti Kotamarti¹ and Veena Patel², ¹Dell Seton Medical Center, Austin, TX, ²Dell Medical School - UT Health Austin, Austin, TX
Background/Purpose: Patients with SLE have high rates of hospitalizations annually and require careful coordination of care in both the inpatient and outpatient setting. Prior analyses…
Abstract Number: 0427 • ACR Convergence 2024
Association of Menopause and Systemic Rheumatic Disease Severity in Peri-Menopausal and Menopausal Women with Systemic Rheumatic Disease
Lucy Masto¹, Amaya Smole², Ranqing Lan¹, Michael Parides¹, Caroline Siegel¹, Sarah Lieber¹, Jonah Levine¹, Bessie Stamm¹, Lisa Mandl¹, Michael Lockshin³, Lisa Sammaritano⁴ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Amherst, MA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, Scarsdale, NY
Background/Purpose: The relationship between menopause and systemic rheumatic disease (SRD) severity in women with SRDs is poorly understood. Few studies evaluating this association suggest worsening…
Abstract Number: 0609 • ACR Convergence 2024
The Mediating Role of Trust in Usual Rheumatologists on the Relationship Between Multidimensional Health Literacy and Medication Adherence Among Japanese Systemic Lupus Erythematosus Patients
Nao Oguro¹, Nobuyuki Yajima², Yuichi Ishikawa³, Natsuki Sakurai⁴, Chiharu Hidekawa⁴, Takanori Ichikawa⁵, Dai Kishida⁵, Keigo Hayashi⁶, Kenta Shidahara⁷, Yoshia Miyawaki⁸, Ryusuke Yoshimi⁹, Kenei Sada¹⁰, Yasuhiro Shimojima⁵ and Noriaki Kurita¹¹, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴Department of Stem Cell and Immune Regulation,Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan, ⁵Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Nagano, Japan, ⁶Brigham and Women’s Hospital, Brookline, MA, ⁷"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁸Center for Innovative Clinical Medicine, Okayama University Hospital Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan, ⁹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Yokohama, Kanagawa, Japan, ¹⁰Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan, ¹¹"Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University Department of Innovative Research and Education for Clinicians and Trainees (DiRECT) Fukushima Medical University Hospital", Fukushima, Fukushima, Japan
Background/Purpose: Maintaining medication adherence is crucial for improving health outcomes among patients with systemic lupus erythematosus, as they require life-long hospital visits and medications. Patients'…
Abstract Number: 0626 • ACR Convergence 2024
Impact of the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) in Systemic Lupus Erythematosus Patients from the Almenara Lupus Cohort
Manuel Ugarte-Gil¹, RV, Gamboa-Cardenas², Victor Pimentel-Quiroz³, Cristina Reategui⁴, Claudia Elera Fitzcarrald⁵, Samira García-Hirsh⁶, José Alfaro-Lozano⁶, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela Alarcon⁷, ¹Universidad Cientifica del Sur, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Lima, Peru, ³Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ⁴Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen/Universidad San Ignacio de Loyola, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Lima, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Physician-reported disease activity has a modest association with patient-reported outcomes (PROs) in systemic lupus erythematosus patients. The aim of this study is to evaluate…
Abstract Number: 0646 • ACR Convergence 2024
Chart Audit of over 1,000 SLE Patients Reveals Biologic Treatment Choice Driven by Disease Manifestations
Maxine Yarnall¹, Ryan Rex² and Sawyer May¹, ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: To better understand how US rheumatologists utilize biologics in the management of SLE, especially among those with cutaneous manifestations. No medication is currently FDA-approved…
Abstract Number: 0664 • ACR Convergence 2024
Impact of Hydroxychloroquine and Belimumab on Early Glucocorticoid Reduction in New-Onset Systemic Lupus Erythematosus: A Retrospective Analysis of Risk and Protective Factors
Takehiro Nakai¹, Sho Fukui², Yukihiko Ikeda³, Hiromichi Tamaki⁴, Mitsumasa Kishimoto⁵ and Masato Okada⁴, ¹St. Luke's International Hospital, Tokyo, Tokyo, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³St Luke's international hospital in Japan, Tokyo, Japan, ⁴St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Glucocorticoid is a critical treatment option for systemic lupus erythematosus (SLE). However, long-term use is associated with numerous side effects and an increased risk…
Abstract Number: 0814 • ACR Convergence 2024
Rare Variants of PAH Risk Genes Associate with a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension
Junyan Qian¹, Xinzhuang Yang², Yu Fang Ding³, qian wang¹, Jiuliang Zhao¹, Weida Liu⁴, Yongtai Liu⁵, Zhuang Tian⁵, Yanhong Wang⁶, Xiaojian Wang⁷, Mengtao Li¹ and Xiaofeng Zeng⁸, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ²Center for Bioinformatics, National Infrastructures for Translational Medicine, Institute of Clinical Medicine & Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, BEIJING, China (People's Republic), ⁴State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ⁶Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁷State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension (PAH) displays significant clinical heterogeneity; nevertheless, the underlying mechanisms remain unclear. Presently, more than twenty risk genes…
Abstract Number: 0982 • ACR Convergence 2024
Urinary Incontinence Among Individuals with Systemic Lupus Erythematosus
Gabriel Salazar¹, Jinoos Yazdany², Courtney Hoge³, S. Sam Lim³, Scott Bauer² and Laura Plantinga⁴, ¹University of California, San Francisco, SF, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Although urinary symptoms are often reported by people with SLE and may substantially affect quality of life, little is known about the burden of…
Abstract Number: 1226 • ACR Convergence 2024
The Problem of Pain in Systemic Lupus Erythematosus: A Comprehensive Analysis of Pain Distribution Using the CHOIR Body Map and PROMIS Measures
Tiffany Jiang¹, Sean Mackey², Beth Darnall², Julia Simard³ and Titilola Falasinnu⁴, ¹Yale School of Medicine, New Haven, CT, ²Stanford School of Medicine, Stanford, ³Stanford School of Medicine, Stanford, CA, ⁴Stanford School of Medicine, Palo Alto, CA
Background/Purpose: Systemic lupus erythematosus (SLE), characterized by an autoimmune attack of healthy tissues, presents a complex collection of symptoms affecting multiple organ systems. Among these,…
Abstract Number: 1276 • ACR Convergence 2024
Therapeutic Drug Monitoring (TDM) of Rituximab to Predict Early B-Cell Repopulation in Children
Rana Alsulami¹, Bindiya Chugani², Joley Johnstone², Ann Yeh², Floris Loeff³, Linda Hiraki², Andrea Knight⁴, Deborah Levy² and Ruud Verstegen², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁴Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Rituximab is increasingly used in pediatric inflammatory diseases, with dosing extrapolated from adult data due to a lack of pediatric-specific pharmacokinetic (PK) information. Children…
Abstract Number: 1491 • ACR Convergence 2024
Self-Reported Cognitive Function Among Older Adults with Systemic Lupus Erythematosus (SLE) Compared to Older Adults with Other Rheumatic and Musculoskeletal Conditions
Patti Katz¹, Sofia Pedro² and Kaleb Michaud³, ¹UCSF, San Rafael, CA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cognitive symptoms such as forgetfulness or “brain fog” are frequently reported in SLE and among the most distressing symptoms of lupus. Cognitive symptoms are…
Abstract Number: 1507 • ACR Convergence 2024
To Develop a Method for Estimating Interferon Signatures in SLE from Routine Clinical Laboratory Tests
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai¹ and Moe Tokunaga³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc., Tokyo, ³Japanese Red Cross Okayama Hospital, Okayama
Background/Purpose: IFN signatures are known to play an important role in the pathogenesis of systemic autoimmune diseases such as SLE. Recently, therapeutic agents targeting IFN…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].